26.5 F
New York
Wednesday, November 29, 2023

BMO upgrades Neurocrine to market perform on Ingrezza outlook (NBIX)

Must read

Share Me


Unrecognizable female doctor holding graphic virtual visualization model of Brain organ in hands. Multiple virtual medical icons.

mi-viri/iStock via Getty Images

BMO Capital Markets has upgraded Neurocrine Biosciences (NASDAQ:NBIX) to market perform, citing its “improved confidence” in the “short-term durability” of the company’s neurological drug Ingrezza, also known as valbenazine.

The investment bank said the upgrade follows a survey of psychiatrists


Source link

- Advertisement -spot_img

More articles


Please enter your comment!
Please enter your name here

Latest article